Soy Component Panel
This assay is used to detect allergen specific-IgE using the ImmunoCAP® FEIA method. In vitro allergy testing is the primary testing mode for allergy diagnosis.
ProcedureThe ImmunoCAP® FEIA method uses as the solid phase a flexible, hydrophobic cellulosic polymer to which allergen has been covalently linked. The advantage of this system is that it has a very high antigen binding capacity when compared to other systems and it has minimal non-specific binding with high total IgE. Viracor Eurofins provides an optional low range calibrator at 0.1 kU/L and a 0/1 class. This test has been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
1-2 business days from receipt of specimen
| Specimen Type | Test Code | CPT Code | NY Approved | Volume | Assay Range | Special Instructions |
|---|---|---|---|---|---|---|
| serum | 403979P | 86008 x 3 | Yes | 1 mL |
See Scoring Guide |
|
ImmunoCAP® Quantitative Scoring Guide:
| Class | IgE (kU/L) | Comment |
| 0 | <0.10 | Negative |
| 0/1 | 0.10-0.34 | Equivocal/Borderline |
| 1 | 0.35-0.69 | Low Positive |
| 2 | 0.70-3.49 | Moderate Positive |
| 3 | 3.50-17.49 | High Positive |
| 4 | 17.50-49.99 | Very High Positive |
| 5 | 50.00-99.99 | Very High Positive |
| 6 | >99.99 | Very High Positive |
Note that Viracor Eurofins includes an extra calibrator at 0.10 kU/L and uses it to
define an optional equivocal class.
Lipemic samples may lead to rejection.
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
ReferencesBallmer-Weber BK, Vieths S. Soy allergy in perspective. Curr Opin Allergy Clin Immunol. 2008 Jun;8(3):270-5. doi: 10.1097/ACI.0b013e3282ffb157.
Holzhauser T, Wackermann O, Ballmer-Weber BK, et al. Soybean (Glycine max) allergy in Europe: Gly m 5 (beta-conglycinin) and Gly m 6 (glycinin) are potential
diagnostic markers for severe allergic reactions to soy. J Allergy Clin Immunol. 2009 Feb;123(2):452-8. doi: 10.1016/j.jaci 2008.09.034. Epub 2008 Nov 8.
Mittag D, Vieths S, Vogen L, et al. Soybean allergy in patients allergic to birch pollen: clinical investigation and molecular characterization of allergens. J Allergy Clin
Immunol. 2004 Jan/113(1):148-54.
Sampson HA. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol. 2001 May:107(5):891-6.
Kosma P, Sjolander S, Landgren E, Borres MP, Hedlin G. Severe reactions after the intake of soy drink in birch pollen-allergic children sensitized to Gly m 4. Acta
Paediatr. 2011 Feb:100(2):305-6.